Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Opiant Pharmaceuticals licenses heroin vaccine from WRAIR and NIDA

Nov. 3, 2016

Hawaii Biotech describes new Botulinum neurotoxin type A light chain inhibitors

Oct. 31, 2016

Omeros reports results from phase II study of PPARgamma agonist in cocaine use disorder

Oct. 20, 2016

U.K. Dstl gets funding to study inhaled ciprofloxacin in biodefense

Oct. 20, 2016

Addex initiates study of ADX-88178 in nonhuman primate model of cocaine addiction

Oct. 11, 2016

Phase II efficacy results for ABT-436 in alcohol-dependent subjects

Oct. 3, 2016

NIH dopamine D3 receptor antagonist VK-4-116 active in substance abuse models

Sep. 12, 2016

Insys Therapeutics enrolls first patient in phase II trial of canabidiol

Aug. 19, 2016

Promising phase III topline results for RBP-6000 monthly depot to treat opioid use disorder

Aug. 17, 2016

Embera Neurotherapeutics receives grant to continue development of drug for cocaine addition

July 27, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...